We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 902

Pfizer case shows protecting your own position isn't anti-competitive

  • Clayton Utz
  • -
  • Australia
  • -
  • March 2 2015

Commercial strategies and practices used by Pfizer to counter the expected loss of revenue caused by the expiry of its patent over Lipitor, its

The right to exploit a patent is a “single indivisible right” - Full Federal Court confirms

  • Corrs Chambers Westgarth
  • -
  • Australia
  • -
  • March 2 2015

In February last year we reported on a decision of Justice Yates of the Federal Court in Bristol-Myers Squibb Company v Apotex Pty Ltd (No 5). Our

ACCC v Pfizer and the future of section 46

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • March 2 2015

The Federal Court has again found against the ACCC in a misuse of market power case, this time involving allegations that Pfizer abused its incumbent

ACCC v Pfizer judgment summary and ramifications

  • Piper Alderman
  • -
  • Australia
  • -
  • February 27 2015

On 25 February 2015, Justice Flick of the Federal Court of Australia ruled in favour of Pfizer Australia Pty Ltd (Pfizer), dismissing the Australian

Parachuting off the patent cliff

  • Gilbert + Tobin
  • -
  • Australia
  • -
  • February 26 2015

Yesterday the Federal court handed down its decision in ACCC v Pfizer. The facts of the case reflect the very significant power of IP rights and the

ACCC pfails in section 46 prosecution in brief

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • February 25 2015

This morning the Federal Court handed down its decision in the misuse of market power proceedings against Pfizer, holding that the ACCC had failed to

Court rejects ACCC claim against Pfizer

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • February 25 2015

The Federal Court has today dismissed a case brought by the Australian Competition and Consumer Commission (ACCC) against Pfizer Australia for

Criteria for pharmaceutical term extensions clarified

  • Shelston IP
  • -
  • Australia
  • -
  • February 20 2015

To compensate patent owners for the time it takes to obtain regulatory and marketing approval for new drugs, the Australian Patents Act provides for

The same but different: heading off generic market entry which does not patent infringe

  • Shelston IP
  • -
  • Australia
  • -
  • February 20 2015

A preliminary discovery application brought in the Federal Court of Australia by GlaxoSmithKline Australia Pty Ltd (GSK) shortly before Christmas has

High Court to consider gene patents: D’arcy granted leave to appeal

  • Davies Collison Cave
  • -
  • Australia
  • -
  • February 20 2015

On the 13 February 2015 the High Court of Australia granted special leave to appeal the decision of the Full Federal Court in D'Arcy v Myriad